DIABETES TREATMENT IN TANZANIA

17 May 1992

Although it is recognized that people afflicted with diabetes mellitus are heavy lifetime users of health care resources in developed countries, few studies have considered the economic implications for developing nations.

However, from the results of a new study conducted at the Muhimbili Medical Center, Das es Salaam, Tanzania, Stella Chale and colleagues report that if presently non-paying African diabetics have to pay for their treatment, as could be in the offing due to severe economic difficulties, most will be unable to do so and will die.

Detailed in the British Medical Journal (May 9), Dr Chale's study was designed to estimate the costs of diagnosis and treatment of diabetes in Tanzania in two groups. The costs were calculated from the reported and recorded experience of a total of 464 patients with newly presenting diabetes between 1989 and 1990 and diabetic patients first seen between 1981 and 1982.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight